Kintors Pyrilutamide meets goal in Phase 2!

[mizmija]

Big news on Pyrilutamide. Lets pray that this is new BIG thing in fighting hair loss.

"Full statistics of the phase 2 trial are not available yet other than the announcement that KX-826 created a statistically significant change in non-vellus hair count in a targeted area compared to placebo."

"The study enrolled 120 male subjects and was completed over a 6 month period. No major adverse events were reported and the majority of adverse events reported were mild"

"With a good safety profile in hand, Kintor Pharmaceutical is planning to commence a phase 3 trial in China by the end of the year."

https://www.folliclethought.com/kintors-kx-826-pyrilutamide-meets-goal-in-phase-2-trial/

[JDEE0]

Phase 3 pegged for the end of the end of the year - Kintor have been moving extremely fast and I have no doubt that this will beat out Breezula to market. 

Let's hope their androgen receptor degrader which is beginning its phase 1 trials is successful - it would undoubtedly be the best treatment we've ever had.

For now though, finasteride stacked with pyrilutamide and perhaps a low dose of oral min daily would really be a 'cure' for anyone at the beginning stages of baldness in my opinion - I think that protocol would keep 99 percent of users steady for pretty much the rest of their lives.

[mizmija]

4 minutes ago, JDEE0 said:

Phase 3 pegged for the end of the end of the year - Kintor have been moving extremely fast and I have no doubt that this will beat out Breezula to market. 

Let's hope their androgen receptor degrader which is beginning its phase 1 trials is successful - it would undoubtedly be the best treatment we've ever had.

For now though, finasteride stacked with pyrilutamide and perhaps a low dose of oral min daily would really be a 'cure' for anyone at the beginning stages of baldness in my opinion - I think that protocol would keep 99 percent of users steady for pretty much the rest of their lives.

Yes, they are great.

As someone who can't tolerate Finasteride, I hope Pyrilutamide will give me something(and GT20029). Until then I am doing anything I can to keep my hair.

[JDEE0]

9 minutes ago, mizmija said:

Yes, they are great.

As someone who can't tolerate Finasteride, I hope Pyrilutamide will give me something(and GT20029). Until then I am doing anything I can to keep my hair.

Have you looked into Dutaseride mesotherapy? From what I've read and heard from credible Dr's such as Bisanga, it is side effect free. That in combination with oral minoxidil should be pretty effective and then you could add Pyrilutamide or whatever comes out when it does.  

But anyway, apparently only mild adverse effects, which is hopefully just some local rash on the scalp or something, and statistically significant changes in hair count. Sounds pretty good, I'll be waiting for the release of the study - hopefully it's pretty soon. 

[MPBdestroyer]

Do we know when the phase 2 results will be released? I've been following pyrilutamide developments like a hawk.

[JDEE0]

9 hours ago, MPBdestroyer said:

Do we know when the phase 2 results will be released? I've been following pyrilutamide developments like a hawk.

We don't know for sure when yet, no, but people are speculating it will likely be in the next few weeks at a dermatology summit/convention. 

Either way, it should be soon. The first patient was dosed in phase 3 clnical trials today; the first time a topical AA has ever made it to phase 3 clinical trials for MPB.

[TorontoMan]

Heres more information for everyone... pretty exciting stuff

[Hairsome]

I've been following this development and it looks interesting. However what would be the price tag of this drug?

Edited January 9, 2022 by Hairsome

[_lshy]

Vibe check - how's this coming along. Anyone on the pulse got something interesting to share?

[MPBdestroyer]

7 hours ago, _lshy said:

Vibe check - how's this coming along. Anyone on the pulse got something interesting to share?

Nothing as far as phase 2 results, but I know people that ordered pyri through a group buy and they should be receiving it sometime in the next few weeks. Fingers crossed pyri is everything we're hoping it is 🤞

[BaldReaper]

Any news here?

[Ghostbusters]

Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound 

 

LLOQ, with the highest not exceeding 0.015 ng/mL.

 

In preclinical studies, by degrading androgen receptor (AR) protein, GT20029 could block the shrinkage and miniaturization of hair follicles which was caused by the activation of AR signaling pathway. As the result, it prevented the hair from thinning, softening and falling out. GT20029 could also effectively inhibit sebaceous gland development and sebum secretion. With limited skin penetration, GT20029 could avoid high systemic exposure and achieve a better safety profile. The repeated pharmacodynamics studies in dihydrotestosterone (DHT)-induced mouse model showed that GT20029 significantly promoted hair growth, with statistical difference. The study of testosterone propionate (TP)-induced skin hamster flank organ acne model showed that GT20029 significantly inhibited enlargement of flank organ, with statistical difference.

 

Dr. Youzhi Tong, founder, Chairman and Chief Executive Officer of Kintor Pharma, commented, “The positive U.S. Phase I top-line results of GT20029 in 123 subjects has shown a similar result with that of Phase I trial in China with 92 subjects enrolled. Both studies have demonsrtated the good safety and tolerability in MAD of GT20029. Alopecia affects about 1.6 billion people and acne affects about 0.72 billion people worldwide, there are huge unmet clinical needs. We will accelerate the initiation of Phase II clinical trial of GT20029, maintain our leading position in the development of topical PROTAC drug candidate globally. We believe that GT20029 would strengthen our market position in the dermatology area, together with our novel drug KX-826, to provide a diversified portfolio of therapies to patients with AGA or acne. ”

 

About GT20029

 

GT20029 is a topical AR degrader developed by Kintor Pharma’s PROTAC platform. The China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) cleared GT20029's clinical trial applications for treating AGA and acne in April 2021 and July 2021, respectively. In August 2022, Kintor Pharma had completed the enrollment and dosing of subjects for its China Phase I clinical trial. In November 2022, Kintor Pharma announced the top-line results for its China phase I clinical trial. In October 2022, Kintor Pharma announced completion of subject enrollment and dosing in its U.S. Phase I clinical trial.

[Fabio69]

On 2/13/2023 at 5:36 AM, Ghostbusters said:

Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound 

 

LLOQ, with the highest not exceeding 0.015 ng/mL.

 

In preclinical studies, by degrading androgen receptor (AR) protein, GT20029 could block the shrinkage and miniaturization of hair follicles which was caused by the activation of AR signaling pathway. As the result, it prevented the hair from thinning, softening and falling out. GT20029 could also effectively inhibit sebaceous gland development and sebum secretion. With limited skin penetration, GT20029 could avoid high systemic exposure and achieve a better safety profile. The repeated pharmacodynamics studies in dihydrotestosterone (DHT)-induced mouse model showed that GT20029 significantly promoted hair growth, with statistical difference. The study of testosterone propionate (TP)-induced skin hamster flank organ acne model showed that GT20029 significantly inhibited enlargement of flank organ, with statistical difference.

 

Dr. Youzhi Tong, founder, Chairman and Chief Executive Officer of Kintor Pharma, commented, “The positive U.S. Phase I top-line results of GT20029 in 123 subjects has shown a similar result with that of Phase I trial in China with 92 subjects enrolled. Both studies have demonsrtated the good safety and tolerability in MAD of GT20029. Alopecia affects about 1.6 billion people and acne affects about 0.72 billion people worldwide, there are huge unmet clinical needs. We will accelerate the initiation of Phase II clinical trial of GT20029, maintain our leading position in the development of topical PROTAC drug candidate globally. We believe that GT20029 would strengthen our market position in the dermatology area, together with our novel drug KX-826, to provide a diversified portfolio of therapies to patients with AGA or acne. ”

 

About GT20029

 

GT20029 is a topical AR degrader developed by Kintor Pharma’s PROTAC platform. The China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) cleared GT20029's clinical trial applications for treating AGA and acne in April 2021 and July 2021, respectively. In August 2022, Kintor Pharma had completed the enrollment and dosing of subjects for its China Phase I clinical trial. In November 2022, Kintor Pharma announced the top-line results for its China phase I clinical trial. In October 2022, Kintor Pharma announced completion of subject enrollment and dosing in its U.S. Phase I clinical trial.

I found this on reddit about GT20029

 

[Heisenberg]

Looks like it may be coming soon.